213 reports of this reaction
3.1% of all ROPIVACAINE HYDROCHLORIDE reports
#8 most reported adverse reaction
PAIN is the #8 most commonly reported adverse reaction for ROPIVACAINE HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 213 FDA adverse event reports linking ROPIVACAINE HYDROCHLORIDE to PAIN. This represents approximately 3.1% of all 6,839 adverse event reports for this drug.
Patients taking ROPIVACAINE HYDROCHLORIDE who experience pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PAIN is moderately reported among ROPIVACAINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to pain, the following adverse reactions have been reported for ROPIVACAINE HYDROCHLORIDE:
The following drugs have also been linked to pain in FDA adverse event reports:
PAIN has been reported as an adverse event in 213 FDA reports for ROPIVACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PAIN accounts for approximately 3.1% of all adverse event reports for ROPIVACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience pain while taking ROPIVACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.